Abstract
Purpose: To evaluate biochemical progression free survival (b-PFS) and toxicity in a consecutive cohort of 76 patients with low risk (LR) and favorable intermediate risk (FIR) prostate carcinoma (PCa) treated with High Dose Rate Monotherapy (HDRM).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
